CAS: 852918-02-6

4-[[[(3-Chloro-4-fluorophenyl)sulfonyl]amino]methyl]benzoic acid (CB2A) is a potentiator that enhances the effects of anandamide, which is a cannabinoid receptor ligand. CB2A binds to the CB2 receptor and increases the concentration of anandamide in the brain. It has been shown to have a favorable safety profile and does not cause seizures or depression. 4-[[[(3-Chloro-4-fluorophenyl)sulfonyl]amino]methyl]benzoic acid has also been shown to inhibit glutamate release and to increase neural activity, as well as to bind with proteins involved in protein synthesis, leading to its potential use for neurologic disorders.

Applications TCN 201 is a novel NMDA receptor antagonist selective for NR2A- over NR2B-containing receptors. References Auberson, Y., et al.: Bioorg. Med. Chem. Lett., 12, 1099 (2002), Yuan, H., et al.: J. Neurosci., 29, 12045 (2009), Bettini, et al.: J. Pharm. Exp. Ther., 335, 644 (2010), Hansen, et al.: J. Neurosci., 32, 6197 (2012),

TCN 201 is a selective antagonist of NMDA receptors containing the NR2A subunit.

TCN 201